Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population
| Autor: | Taisei Mushiroda, Atsushi Takahashi, Michiaki Kubo, Yuji Shirakata, Yusuke Nakamura, Naoyuki Kamatani, Tetsuo Shiohara, Zenro Ikezawa, Amara Yowang, Koji Hashimoto, Takeshi Ozeki, Masafumi Iijima |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Linkage disequilibrium medicine.medical_specialty Adolescent Drug-Related Side Effects and Adverse Reactions Genotype Population Single-nucleotide polymorphism Genome-wide association study Biology Cohort Studies Young Adult Asian People Japan Genetics medicine Humans Genetic Predisposition to Disease Allele Child education Molecular Biology Alleles Genetics (clinical) Aged Aged 80 and over education.field_of_study HLA-A Antigens Infant General Medicine Odds ratio Middle Aged medicine.disease Dermatology Toxic epidermal necrolysis Carbamazepine Child Preschool Anticonvulsants Female Genome-Wide Association Study |
| Zdroj: | Human Molecular Genetics. 20:1034-1041 |
| ISSN: | 1460-2083 0964-6906 |
| DOI: | 10.1093/hmg/ddq537 |
| Popis: | An anticonvulsant, carbamazepine (CBZ), is known to show incidences of cutaneous adverse drug reactions (cADRs) including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug-induced hypersensitivity syndrome (DIHS). To identify a gene(s) susceptible to CBZ-induced cADRs, we conducted a genome-wide association study (GWAS) in 53 subjects with the CBZ-induced cADRs, including SJS, TEN and DIHS, and 882 subjects of a general population in Japan. Among the single nucleotide polymorphisms (SNPs) analyzed in the GWAS, 12 SNPs showed significant association with CBZ-induced cADRs, and rs1633021 showed the smallest P-value for association with CBZ-induced cADRs (P = 1.18 × 10⁻¹³). These SNPs were located within a 430 kb linkage disequilibrium block on chromosome 6p21.33, including the HLA-A locus. Thus, we genotyped the individual HLA-A alleles in 61 cases and 376 patients who showed no cADRs by administration of CBZ (CBZ-tolerant controls) and found that HLA-A*3101 was present in 60.7% (37/61) of the patients with CBZ-induced cADRs, but in only 12.5% (47/376) of the CBZ-tolerant controls (odds ratio = 10.8, 95% confidence interval 5.9-19.6, P = 3.64 × 10⁻¹⁵), implying that this allele has the 60.7% sensitivity and 87.5% specificity when we apply HLA-A*3101 as a risk predictor for CBZ-induced cADRs. Although DIHS is clinically distinguished from SJS and TEN, our data presented here have indicated that they share a common genetic factor as well as a common pathophysiological mechanism. Our findings should provide useful information for making a decision of individualized medication of anticonvulsants. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|